FDA Brief

Warning letters Drugs

FDA warning letter to

International Laboratories Corp. Ltd.

High riskIssued Aug 8, 2023Posted Aug 22, 2023Center for Drug Evaluation and Research | CDER

International Laboratories Corp. Ltd. failed manufacturing-practice rules for OTC drugs, including component identity testing and quality-unit oversight.

What happened

FDA found this by reviewing records the company submitted after a March 17, 2023 request; no inspection dates are listed. FDA found the company did not test each shipment of each lot of high-risk components for identity, including United States Pharmacopeia (USP) limit tests for hazardous impurities, and that its quality unit did not adequately approve or reject components.

What FDA found

  1. The company did not perform at least one identity test on each incoming component lot, including high-risk components that needed USP limit tests for hazardous impurities.

    21 CFR 211.84(d)(1)
  2. The company's quality unit did not adequately exercise its responsibility to approve or reject components and other materials.

    21 CFR 211.22(a)

What FDA wants

FDA tells the company to respond in writing within 30 working days with what it has done to fix the violations and prevent recurrence. FDA also asks for a commitment and test results for high-risk components no later than 30 calendar days, and if corrective actions cannot be completed within 15 working days, the company must explain the delay and give a schedule.

Who should pay attention

  • US importers and distributors of OTC drug products
  • brands that buy finished OTC drugs from this contract manufacturer
  • companies relying on supplier certificates of analysis for component identity

This is a summary. Read the original letter on fda.gov.

International Laboratories Corp. Ltd.'s FDA history

  1. International Laboratories Corp

    FDA warned International Laboratories Corp, a Thai drug manufacturer, over fabricated lab records and inadequate CGMP controls.

    High risk

Full company page

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk